john abeles

JOHN H. ABELES, M.D. Dr Abeles was born in 1945 in Rhodesia (now Zimbabwe). He received his Medical degree as well as a degree in Pharmacology from the University of Birmingham, England, in 1969. He practised Medicine in London, before joining the Pharmaceutical Industry in 1971 as a Senior Medical Executive, with Sterling Drug in the UK, and then from 1973 with Pfizer Inc and Revlon Health Care in the USA. In 1975 he became the first, full-time Wall Street health-care analyst with MD qualifications, at Kidder Peabody, until 1980 when he formed MedVest Inc and later Northlea Partners. During this time he had a part-time medical practice in Westport, Connecticut. Since March 1982, Dr. Abeles has been the Founder, Sole Investor and General Partner of Northlea Partners Ltd., a venture and private capital, family partnership headquartered in Boca Raton, Florida, which has had numerous investments, both active and passive, in the healthcare field. Since 1980, Dr. Abeles has also been President of MedVest Group, Inc., a business and financial consulting firm. He has been instrumental in helping promulgate many early stage medical and other companies; some are still private and several have emerged into the public arena. Some of those have been acquired by major industrial and financial groups. He was a Managing Member of ProMed Capital LLC, a New York investment group promulgating Israeli medical venture companies and investments. ProMed has initiated three major Israeli investments: *Althera Medical (local, alpha-particle brachytherapy treatment of solid tumors); *Allium -- previously Endogun Surgical-- (surgical system for gynecology and urology surgery; Israeli medtech roll-up strategies); *HDH Medical ( stitchless vascular anastomosis system). Dr Abeles is an Adviser to HDH and an ex- Director of Althera. Dr. Abeles was a Founder and has served on the Board of *I-Flow Corporation, a company that manufactures infusion devices (and was acquired by KimberlyClark for approximately $400 million). He was an Adviser and longtime past Director of *DUSA Pharmaceuticals, Inc., a publicly traded company, which is developing dermatology and photodynamic therapy products. It has been acquired by SunPharma of India for around $250 million. He was a primary financier and Director of *Encore Medical, an orthopedics and physical medicine company acquired for approximately $800 million by the Blackstone Group, a private equity concern. He was a Director of *Combimatrix, a publicly traded genetic diagnostics company. Currently, he serves as a Director of *CytoCore, Inc, which is a public company researching medical diagnostic equipment and reagents. Regarding past associations with public companies, he had been a Founder/Director of *Procyte Inc (acquired by Photomedex); *Imre Corp (acquired by Fresenius) and *Epitope Inc (acquired by Orasure). He also served as a Director of and investor in *SysteMed, a company acquired by Merck. Regarding private companies, he is a Director of *Alison Raffaele Cosmetics; *Unimedica (medical education-- owner of a paradigm changer in an e-learning enabled medical school, IUHS); and *Etubics (viral vectors for gene delivery); and a Founder/Director of *Centaur Inc (biomedical products for large animal veterinary markets) He was a Director of *Textronics which was acquired by Adidas. He was a founder shareholder and Director of *Insonus Medical, an advanced hearing aid company in the SF Bay Area and acquired by Sonova of Switzerland, the leading hearing aid company in the world. He is an investor and Director of *OHK Medical, an Israeli/USA company marketing a novel device for enabling bloodless operating fields in orthopedic surgery as well as other applications He is a Founder, past Director of and a major early investor in *ContraFect Inc (anti-infective monoclonal antibody immunology and enzymology). He is a Chairman, Founder of *Neurotrope BioSciences, a newly-formed company developing advanced therapeutics and diagnostics for Alzheimer's Disease and other neurodegenerative disorders. He recently has become Founder/Investor in and joined the Board of *Serpin Pharma, an early-stage peptide company in the anti-inflammatory and antidiabetic fields. He is also a Founder/Director of a new anticancer peptide company, *OncoLyze Therapeutics. Dr Abeles serves as an Advisory Board Member of the College of Chemistry, University of California, Berkeley, He is on the Advisory Board of the Higuchi BioSciences Institute at the University of Kansas. He is a Fellow of the Royal Society of Medicine, London.

IUHS --- www.iuhs.edu --- is a medical school that uses an live and archived, online teaching method -- where distant students who are health professionals (nurses; nurse practitioners; physician assistants; pharmacists; physical therapists; psychologists; health scientists and science postgrads) who have verified hospital access, can use that access for the practical portion of the first two years of instruction. They study to become physicians. A mentor physician -- appointed as an honorary adjunct professor -- is chosen of assigned to the student. Standards are high, costs and fees low (the capital and staffing expenses are kept low -- with the 'other peoples walls' online education concept -- during a large, worldwide student expansion)... This is a low cost solution to the severe physician -- especially primary care -- shortage worldwide at a much reduced expense to the student.